News headlines about SeaSpine (NASDAQ:SPNE) have trended somewhat positive on Wednesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. SeaSpine earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 47.0447879099988 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Shares of SeaSpine (SPNE) traded down $0.01 on Wednesday, reaching $9.99. The company’s stock had a trading volume of 26,975 shares, compared to its average volume of 37,168. The company has a market cap of $145.38, a price-to-earnings ratio of -3.83 and a beta of 0.36. SeaSpine has a 52-week low of $6.31 and a 52-week high of $13.46.

SeaSpine (NASDAQ:SPNE) last announced its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.56) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $33.98 million during the quarter. SeaSpine had a negative net margin of 24.36% and a negative return on equity of 29.96%. equities analysts predict that SeaSpine will post -1.99 earnings per share for the current year.

A number of research firms recently commented on SPNE. BTIG Research restated a “buy” rating and set a $17.00 price target on shares of SeaSpine in a research report on Friday, March 2nd. HC Wainwright set a $15.00 price target on SeaSpine and gave the stock a “buy” rating in a research report on Friday, March 2nd. Zacks Investment Research lowered SeaSpine from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Finally, Ladenburg Thalmann Financial Services began coverage on SeaSpine in a research report on Thursday, December 14th. They set a “buy” rating and a $20.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.20.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at

About SeaSpine

SeaSpine Holdings Corporation is a medical technology company. The Company is focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. The Company operates through the development, manufacture and marketing of orthobiologics and spinal fusion hardware segment.

Insider Buying and Selling by Quarter for SeaSpine (NASDAQ:SPNE)

Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with's FREE daily email newsletter.